Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 19;19(4):997-1004.
doi: 10.1007/s10433-022-00735-w. eCollection 2022 Dec.

Preclinical Alzheimer's dementia: a useful concept or another dead end?

Ruth E Mark  1 , Yvonne Brehmer  2   3
Affiliations
Review

Preclinical Alzheimer's dementia: a useful concept or another dead end?

Ruth E Mark et al. Eur J Ageing. .

Abstract

The term, preclinical dementia, was introduced in 2011 when new guidelines for the diagnosis of Alzheimer's dementia (AD) were published. In the intervening 11 years, many studies have appeared in the literature focusing on this early stage. A search conducted in English on Google Scholar on 06.23.2022 using the term "preclinical (Alzheimer's) dementia" produced 121, 000 results. However, the label is arguably more relevant for research purposes, and it is possible that the knowledge gained may lead to a cure for AD. The term has not been widely adopted by clinical practitioners. Furthermore, it is still not possible to predict who, after a diagnosis of preclinical dementia, will go on to develop AD, and if so, what the risk factors (modifiable and non-modifiable) might be. This Review/Theoretical article will focus on preclinical Alzheimer's dementia (hereafter called preclinical AD). We outline how preclinical AD is currently defined, explain how it is diagnosed and explore why this is problematic at a number of different levels. We also ask the question: Is the concept 'preclinical AD' useful in clinical practice or is it just another dead end in the Holy Grail to find a treatment for AD? Specific recommendations for research and clinical practice are provided.

Keywords: Alzheimer’s dementia; Biomarkers; Ethics; Mild cognitive impairment; Preclinical (Alzheimer’s) dementia.

PubMed Disclaimer

References

    1. AD Protect and Prevent tool see: https://www.addp.eu/press-release-launch/
    1. Ahmad S, Orrell M, Iliffe S, Gracie A. GPs' attitudes, awareness, and practice regarding early diagnosis of dementia. Br J Gen Pract 1. 2010;60(578):360–365. doi: 10.3399/bjgp10X515386. - DOI - PMC - PubMed
    1. Alexopoulos P, Kurz A. The new conceptualization of Alzheimer’s disease under the microscope of influential definitions of disease. Psychopathology. 2015;2015(48):359–367. doi: 10.1159/000441327. - DOI - PubMed
    1. Ashford JW, Tarpin-Bernard F, Ashford CB, Ashford MT. A computerized continuous-recognition task for measurement of episodic memory. J Alzheimer’s Dis. 2019;69:385–399. doi: 10.3233/JAD-190167. - DOI - PMC - PubMed
    1. Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement. 2015;11(6):718–726. doi: 10.1016/j.jalz.2015.05.016. - DOI - PubMed

LinkOut - more resources